Pediatrics

Positive trial results for RSV infant treatment: Sanofi

French pharmaceutical giant Sanofi announced trial results on Friday that showed its preventative treatment for respiratory syncytial virus (RSV) reduced the rate of babies being hospitalized by more than 80 percent.

Diseases, Conditions, Syndromes

RSV: We finally have a vaccine for this deadly virus

The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration. The vaccine, named Arexvy, will be given to people 60 years and older.

Diseases, Conditions, Syndromes

FDA approves first RSV vaccine

The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.

Vaccination

EU watchdog backs GSK's RSV vaccine for over 60s

The European Union's drug watchdog has recommended approval of pharmaceutical giant GSK's vaccine against the RSV respiratory virus for over-60s, the British firm said on Thursday.

Diseases, Conditions, Syndromes

Study links infant RSV to childhood asthma

Research led by Vanderbilt University Medical Center has sought a connection between the respiratory virus RSV in infants and asthma in 5-year-olds. The paper, "Respiratory syncytial virus infection during infancy and asthma ...

Pediatrics

Pandemic disrupted respiratory syncytial virus season timing

The typical timing of seasonal respiratory syncytial virus (RSV) epidemics (October to April) was disrupted during the COVID-19 pandemic, according to research published in the April 7 issue of the U.S. Centers for Disease ...

page 10 from 26